SG Americas Securities LLC Grows Stock Position in Ikena Oncology, Inc. (NASDAQ:IKNA)

SG Americas Securities LLC lifted its stake in Ikena Oncology, Inc. (NASDAQ:IKNA) by 88.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,222 shares of the company’s stock after buying an additional 9,495 shares during the quarter. SG Americas Securities LLC’s holdings in Ikena Oncology were worth $40,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. boosted its position in Ikena Oncology by 0.6% in the 1st quarter. BlackRock Inc. now owns 307,234 shares of the company’s stock worth $1,060,000 after purchasing an additional 1,818 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Ikena Oncology by 5.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 66,810 shares of the company’s stock valued at $408,000 after buying an additional 3,276 shares during the period. JPMorgan Chase & Co. grew its position in Ikena Oncology by 25.4% during the first quarter. JPMorgan Chase & Co. now owns 17,172 shares of the company’s stock valued at $104,000 after buying an additional 3,482 shares during the period. Dimensional Fund Advisors LP increased its holdings in Ikena Oncology by 14.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 28,682 shares of the company’s stock valued at $77,000 after buying an additional 3,537 shares in the last quarter. Finally, Barclays PLC raised its position in shares of Ikena Oncology by 2.1% in the second quarter. Barclays PLC now owns 202,202 shares of the company’s stock worth $1,326,000 after acquiring an additional 4,161 shares during the period. 75.00% of the stock is owned by institutional investors and hedge funds.

Ikena Oncology Stock Up 5.6 %

IKNA stock opened at $1.33 on Monday. Ikena Oncology, Inc. has a 52 week low of $1.02 and a 52 week high of $7.64. The firm has a 50-day simple moving average of $1.41 and a 200-day simple moving average of $1.99. The stock has a market capitalization of $64.19 million, a P/E ratio of -0.81 and a beta of 0.33.

Ikena Oncology (NASDAQ:IKNA) last posted its quarterly earnings data on Tuesday, March 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.41). The firm had revenue of $0.66 million during the quarter, compared to analyst estimates of $2.39 million. On average, analysts expect that Ikena Oncology, Inc. will post -1.5 earnings per share for the current year.

Analysts Set New Price Targets

IKNA has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Ikena Oncology in a research note on Tuesday, March 19th. Wedbush reiterated an “outperform” rating and set a $8.00 target price on shares of Ikena Oncology in a research report on Tuesday, March 12th.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.